Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Anaplastic Astrocytoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Astrocytoma (74)

Astrocytoma (74)

›

No biomarker	Anaplastic Astrocytoma	No biomarker	Anaplastic Astrocytoma	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1
No biomarker	Anaplastic Astrocytoma	No biomarker	Anaplastic Astrocytoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
IDH1 R132H	Anaplastic Astrocytoma	IDH1 R132H	Anaplastic Astrocytoma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
MGMT promoter methylation	Anaplastic Astrocytoma	MGMT promoter methylation	Anaplastic Astrocytoma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
BRAF V600	Anaplastic Astrocytoma	BRAF V600	Anaplastic Astrocytoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
NRAS mutation	Anaplastic Astrocytoma	NRAS mutation	Anaplastic Astrocytoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3
IDH2 mutation	Anaplastic Astrocytoma	IDH2 mutation	Anaplastic Astrocytoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
IDH1 mutation	Anaplastic Astrocytoma	IDH1 mutation	Anaplastic Astrocytoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
ABCB1 G412G	Anaplastic Astrocytoma	ABCB1 G412G	Anaplastic Astrocytoma	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
TMB-H	Anaplastic Astrocytoma	TMB-H	Anaplastic Astrocytoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
NACC2-NTRK2 fusion	Anaplastic Astrocytoma	NACC2-NTRK2 fusion	Anaplastic Astrocytoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation	Anaplastic Astrocytoma	IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation	Anaplastic Astrocytoma	carboplatin + temozolomide + vincristine Resistant: C4 – Case Studies carboplatin + temozolomide + vincristine Resistant : C4	carboplatin + temozolomide + vincristine Resistant: C4 – Case Studies carboplatin + temozolomide + vincristine Resistant : C4
BRAF mutation	Anaplastic Astrocytoma	BRAF mutation	Anaplastic Astrocytoma	dabrafenib Sensitive: C4 – Case Studies dabrafenib Sensitive : C4	dabrafenib Sensitive: C4 – Case Studies dabrafenib Sensitive : C4